21 Jun 2021
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2021/06/21/2250101/0/en/Oyster-Point-Pharma-Announces-Enrollment-of-First-Subject-in-the-OLYMPIA-Phase-2-Clinical-Trial-of-OC-01-varenicline-Nasal-Spray-for-Patients-with-Neurotrophic-Keratopathy.html